Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec

Roche’s plans for expanding Tecentriq in early-stage cancers have hit a snag. But the company’s newly minted pharma chief remains hopeful for an important trial in resectable lung cancer.